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Abstract 
Background: Studies of the associations between in utero 25-hydroxyvitamin D [25(OH) D] 
exposure and childhood asthma risk, wheeze and respiratory tract infections are inconsistent and 
inconclusive.  
 
Objectives: To assess the associations between 25(OH) D levels in cord blood or maternal 
venous blood and risk of offspring’s asthma, wheeze and respiratory tract infections. 
 
Methods: Data were derived from PubMed, EMBASE, Google Scholar, references from 
relevant articles, and de novo results from published studies until December, 2015.  Random-
effects meta-analysis was conducted among 16 birth cohort studies. 
 
Results: Comparing the highest to the lowest category of 25 (OH) D levels, the pooled ORs 
were 0.84 (95% CI, 0.70 to 1.01; P = 0.064) for asthma, 0.77 (0.58 to 1.03; P = 0.083) for 
wheeze, and 0.85 (0.66 to 1.09; P = 0.187) for respiratory tract infections. The observed inverse 
association for wheeze was more pronounced and became statistically significant in the studies 
that measured 25 (OH) D levels in cord blood (0.43, 0.29 to 0.62; P < 0.001).  
 
Conclusions: Accumulated evidence generated from this meta-analysis suggests that increased 
in utero exposure to 25 (OH) D is inversely associated with the risk of asthma and wheeze during 
childhood. These findings are in keeping with the results of two recently published randomized 
clinical trials of vitamin D supplementation during pregnancy.   
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Key Messages 
 Two recent randomized clinical trials suggest a non-significant protective effect of prenatal 
vitamin D supplementation on the risk of persistent wheeze/asthma in early childhood. 
However, the trials may be underpowered. 
 After meta-analyzing data from 16 birth cohorts, we show that increased in utero exposure 
to 25 (OH) D is inversely related to risk of offspring’s asthma and wheeze, but not 
respiratory tract infections.  
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Capsule Summary 
 Combining data from 16 birth cohort studies, this meta-analysis suggests that in utero 
exposure to 25(OH) D is inversely associated with risk of offspring’s wheeze and asthma 
during childhood, supporting findings from two recent RCTs.  
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INTRODUCTION 
Asthma, characterized by variable airway obstruction, wheeze, bronchial hyper-responsiveness 
and airway inflammation,1 is very common worldwide and usually starts in childhood.2 While 
allergic constitution, sensitization to allergens3-5 and/or familial history of allergic disease6 are 
recognized risk factors for asthma, studies also suggest that maternal vitamin D status during 
pregnancy may be associated with the risk of asthma in childhood.7,8 To date, some birth cohort 
studies have shown that vitamin D status may play an important role in the development of fetal 
lungs.9-11 Also, epidemiologic studies  have suggested that maternal vitamin D intake12, 13 as well 
as vitamin D levels in blood14-16 were inversely associated with respiratory tract infections and 
other wheezing illnesses, presumably because of its multiple immune effects including induction 
of antibacterial responses and modulation of T-lymphocytes to suppress inflammation.17,18 Data 
from randomized clinical trials are sparse, but two recently-published trials reported a non-
significant more than 20% reduced risk of persistent wheeze/asthma at age 0-3 years from 
prenatal vitamin D supplementation19,20 In addition to the relatively short follow-up period, the 
investigators acknowledged that the studies might be underpowered. 
 
A systematic review of 3 cohort studies qualitatively summarized the evidence suggesting a 
potential link between serum levels of vitamin D and the diagnosis of asthma in childhood.21 
Another systematic review of 23 published articles including 9 cross-sectional, 2 case-control, 
and 12 cohort studies in both children and adults suggested that higher serum levels of 25-
hydroxyvitamin D [25(OH) D] were associated with lower risk of asthma exacerbations, but 
provided little evidence on whether lower in utero exposure to 25(OH) D has a programming 
effect on development of asthma in childhood.22 Notably, neither of these reviews considered 
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wheeze and respiratory tract infections as outcomes. 
 
Since placental transfer of 25(OH) D is the major source of vitamin D in the developing fetus, 
we conducted this meta-analysis to quantitatively summarize the up-to-date literature to examine 
the overall associations between 25 (OH) D levels of cord blood or maternal venous blood and 
risk of childhood asthma, wheeze, and respiratory tract infections.  
 
METHODS 
Search strategy and selection criteria 
Two investigators (HF and PX) scrutinized publications independently based on the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.23 The 
complete search process is outlined in Fig 1 and the completed PRISMA checklist is available in 
E Table 1 at the Online Repository. First, PubMed [1966-] and EMBASE [1974-] were searched 
from inception to December 31, 2015 using the terms “vitamin D” and “lung disease or asthma 
or respiratory tract diseases” and “epidemiological studies” and “cohort / prospective or follow-
up or longitudinal studies”. Second, Google Scholar was used to search for any other studies that 
were not identified from the aforementioned literature review. Third, the references from the 
retrieved articles were manually searched for possible additional studies. Conference abstracts 
and unpublished studies were not included. Finally, to get additional information, we requested 
de novo data specifically for this meta-analysis from some primary studies.24-26  
 
The following inclusion criteria were used in this meta-analysis: 1) English article; 2)  
prospective birth cohort design; 3) cord blood or maternal venous blood 25 (OH) D levels as 
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exposure; 4) offspring’s asthma, wheeze or respiratory tract infections, which were diagnosed by 
physicians or meeting the international guidelines, or the parents reported as outcomes; and 5) 
available data on the relevant odds ratio (OR) or relative risk (RR) or hazards ratio (HR) and the 
corresponding 95% confidence intervals (CIs).  
 
Quality assessment and data extraction 
Two investigators (HF and PX) independently evaluated the quality of each primary study based 
on the criteria derived from the Newcastle-Ottawa quality assessment scale (NOS) with a 
maximum score of 9 points.27 Any discrepancy was adjudicated by a third reviewer (KH). The 
NOS for cohort studies was divided into three groups: selection of cohort (4 points), 
comparability of cohort (2 points) and assessment of outcome (3 points). The quality of study 
was considered high or moderate if the sum score was ≥ 8 points or between 5-7 points, 
respectively. We limited our meta-analysis to those studies that were rated as high or moderate 
quality. One study was excluded from the main analysis due to low quality.28 E Table 2 at the 
Online Repository shows the details of the study quality assessment.  
 
Data were extracted from all the eligible studies by two independent researchers (HF and PX) 
based on a standardized form, and any controversy was resolved through consensus by 
discussion with a third researcher (KH). From each included study, we extracted the following 
information: name of the first author, year of publication, the country of origin, study name, 
proportion of boys, duration of follow-up, numbers of participants/events, exposure assessment 
and categorization, outcome definition and assessment, adjusted covariates in the final model, 
and the OR / RR / HR estimates with corresponding 95%CIs for all categories and/or continuous 
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exposure of interest.   
 
To examine dose-response relationship, linear associations were standardized to per 10 nmol/L 
increment in blood 25 (OH) D levels. If the linear association was not reported in the primary 
study, we estimated it using Greenland and Longnecker’s generalized least square method if the 
participants and the events in each category were available, or using variance-weighted least-
squares estimation if this information was unavailable.29,30. If the highest exposure category was 
open-ended (e.g., >89 nmol/L), its upper limit was determined by assuming its range was the 
same interval as that of the adjacent category. Twelve out of 16 included studies reported ORs 
(95%CIs). In addition, we obtained de novo data for ORs (95%CIs) from two studies,25,26 and 
converted RRs (95%CIs) to ORs (95%CIs) in other two studies31,32  by using the formula: OR = 
[(1-P0)*RR/(1-RR*P0)], where P0 indicated the incidence of the outcome of interest in the non-
exposed/reference group.33  
 
Statistical analysis 
The ORs and corresponding 95%CIs extracted from individual studies were transformed into 
natural logarithms to normalize their distribution, stabilize the variances, and facilitate the 
calculation of its standard errors. The pooled ORs and corresponding 95%CIs for each outcome 
of interest were computed using a random-effects model by weighting the inverse of variance. To 
get the pooled association for risk of asthma and wheeze, we pooled the two outcomes within 
each study first using a random-effects model if the study reported both of the two outcomes. 
The heterogeneity among studies was tested by Cochran’s Q test with a significance level of 0.10 
and quantified by the I2 statistic. An I2 value of 0-25%, 26-50%, 51-75%, or >75% represents no, 
11 
 
low, moderate, or high heterogeneity, respectively. Publication bias was determined by Egger’s 
regression asymmetry test also with a significance level of 0.1 The Duval and Tweedie 
nonparametric "trim and fill" method was used to adjust for publication bias if applicable.34  
 
Stratified analyses were performed to determine modification effects by a few pre-specified 
factors, including blood source (cord blood vs. maternal venous blood), outcome diagnosis 
(clinician diagnosis vs. parental report), and season variation consideration (yes vs. no). A 
random-effects meta-regression model was used to obtain the P value for interaction between 
each of these factors and the exposure.35 Sensitivity analyses were conducted to evaluate the 
influence of replacing a random-effects model with a fixed-effects model and the influence of a 
single study on the associations by omitting one primary study each time in the meta-analysis.  
 
All analyses were performed by using STATA statistical software (Version 13.0; STATA 
Corporation LP, College Station, Texas, USA). A two-sided P value ≤ 0.05 was considered 
statistically significant if not otherwise specified. 
 
RESULTS 
Literature search  
Fig 1 shows the flow of the study selection process. A total of 130 articles in PubMed and 356 in 
EMBASE were identified initially. Of them, 8 in PubMed (5 reviews and 3 case reports) and 102 
in EMBASE (28 reviews and 74 case reports) were excluded. Also, 111 in PubMed and 249 in 
EMBASE were excluded after reviewing the title and abstract. Of the 11 studies in PubMed and 
5 in EMBASE, 3 studies were further excluded after full-text review because of substantial 
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overlap with other studies. In addition, 4 studies were found via Google Scholar. Thus, by 
systematically searching the literature, 17 studies10,11,24-26,31-33,36-44 were identified. After quality 
assessment, one study was excluded.33 Finally, 16 birth cohort studies were included in this 
meta-analysis. 
 
Study characteristics 
Characteristics of the 16 included studies are summarized in E Table 3 at the Online Repository. 
These primary studies were conducted in Asia,38,40,43 Europe,10,24-26,31,32,36,41,44 North America,42 
and Australia.11,37,39 Of the 16 studies, 10 studies focused on asthma, including 8 871 participants 
(1 494 incident cases) with an average 5.9-year follow-up; 10 studies reported results on wheeze, 
including 9 072 individuals (2 277 incident cases) with an average 5.5-year follow-up; and 10 
studies presented findings on respiratory tract infections, including 8 359 individuals (2 562 
incident cases) with an average 1.4-year follow-up. The blood 25(OH) D levels were measured 
with various methods including chemiluminescence immunoassay (CLIA), 
electrochemiluminescence (ECL), enzyme immunoassay (EIA), high-performance liquid 
chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS), high-
performance liquid chromatography-tandem mass spectrometry (HPLC-MS), and 
radioimmunoassay (RIA). The blood samples were either cord blood or maternal venous blood 
during pregnancy in different stages. Seven studies were evaluated as high quality,24-26,36,37,40,44 
while the other 9 studies as moderate quality.10,11,29,30,38,39,41-43 
 
Primary analyses 
Asthma  
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According to the available data from 8 studies,10,11,24-26, 37,38,41 a borderline significant inverse 
association between in utero exposure to vitamin D and risk of asthma in offspring was found. 
The pooled OR for the offspring’s asthma was 0.84 (95%CI, 0.70 to 1.01; P = 0.064) comparing 
the highest to the lowest category of 25 (OH) D levels (Fig 2). No evidence of heterogeneity (I2 = 
10.4%, P = 0.349) and publication bias (Egger’s test: P = 0.308) was found.  
 
No statistically significant linear association was observed based on available data derived from 
8 studies.10,24-26,36,37,41,42 The pooled OR for the offspring’s asthma was 0.99 (95%CI, 0.97 to 
1.02; P = 0.691) with a 10 nmol/L increment in 25 (OH) D levels. Neither heterogeneity (I2 = 
0.0%, P = 0.520) nor publication bias (Egger’s test: P = 0.570) was evidenced.  
 
Wheeze  
Similar to asthma, a borderline significant inverse association was observed between in utero 
exposure to vitamin D and risk of wheeze in offspring when combining data from 8 eligible 
studies.11, 24-26,31,37,41,44 The pooled OR for wheeze was 0.77 (95%CI, 0.58 to 1.03; P = 0.083) 
comparing the highest to the lowest category of 25 (OH) D levels (Fig 3). A moderate 
heterogeneity exists across included studies (I2 = 62.1%, P = 0.010). No publication bias was 
evident (Egger’s test: P = 0.122).  
 
No statistically significant linear association was determined using available data from 9 studies. 
24-26,31,36,37,39,41,44 The pooled OR for offspring’s wheeze was 0.98 (95%CI, 0.96 to 1.004; P  = 
0.114) with every 10 nmol/L increment in 25 (OH) D levels. No heterogeneity (I2 = 5.3%, P = 
0.391) nor publication bias (Egger’s test: P = 0.286) exists.  
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Respiratory tract infections  
Ten studies examined cord blood or maternal venous blood25 (OH) D levels in relation to 
offspring’s respiratory tract infections.11,24,25,31,32,37,40,41,43,44 The combined results did not reveal a 
significant inverse association. The pooled OR was 0.85 (95%CI, 0.66 to 1.09; P = 0.187) as 
compared the highest to the lowest category of 25 (OH) D levels (Fig 4). No evidence on 
publication bias (Egger’s test: P = 0.486), but a moderate heterogeneity existed across included 
studies (I2 = 66.1%, P = 0.003).  
 
A non-significant linear association was found. The pooled OR was 0.97 (95%CI, 0.94 to 1.01; P 
= 0.156) with a 10 nmol/L increment in 25 (OH) D levels. Neither heterogeneity (I2 = 0.0%, P = 
0.495) nor publication bias (Egger’s test: P = 0.798) existed. 
 
Stratified analysis 
We examined potential effect modifications of a few pre-specified factors (Table 1). The 
association with risk of wheeze was modified by the source of 25 (OH) D (P for interaction = 
0.007). A statistically significant inverse association was documented when combining data from 
studies with 25(OH) D measured in cord blood. The pooled OR was 0.43 (95%CI, 0.29 to 0.62; 
P < 0.001) comparing the highest to the lowest category of cord blood 25(OH) D levels. The risk 
of offspring’s wheeze was lowered by 5% with every 10 nmol/L increment in cord blood 25 
(OH) D levels (0.95, 95%CI, 0.91 to 0.99; P = 0.009). By contrast, no significant association was 
found when combining studies with 25(OH) D measured in maternal venous blood. Other factors 
including outcome diagnosis and season variation consideration did not appreciably modify the 
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associations of interest. Of note, one primary study11 reported sex difference. Hence, we 
requested de novo data on sex difference and received data from 3 primary studies.24-26 After 
combining data from these 4 available studies, no significant sex difference was found (data not 
shown). 
 
Sensitivity analysis 
When replacing a random-effects model with a fixed-effects model, the results were generally 
consistent, except that the association between in utero exposure to 25 (OH) D (highest vs. 
lowest) and risk of respiratory tract infection became statistically significant (0.93; 95%CI, 0.91 
to 0.95; P < 0.001) (E Table 4 at the Online Repository). Since the most common cause of 
recurrent wheezing is asthma attacks, we combined these two endpoints with available data from 
10 studies.10,11,24-26,31,37,38,41,44  The pooled OR was 0.80 (95% CI, 0.66 to 0.98; P = 0.028) 
comparing the highest to the lowest category of 25 (OH) D levels. 
 
A couple of studies substantially affect the pooled results (E Table 5 at the Online Repository). 
The overall association between 25 (OH) D and asthma was strengthened and became 
statistically significant when the study by Camargo and colleagues37 (Categorical analysis: 0.82; 
95%CI, 0.67 to 0.999; P = 0.049) or the study by Wills and colleagues26 (Categorical analysis: 
0.78; 95%CI, 0.64 to 0.96; P = 0.017) was omitted. Similarly, the overall association between 25 
(OH) D and wheeze was strengthened and became statistically significant by omitting the study 
by de Jongh and colleagues31 (Categorical association: 0.72; 95%CI, 0.53 to 0.99; P = 0.041) or 
by omitting the study by Wills and colleagues26 (Linear association: 0.97; 95%CI, 0.95 to 
0.9996; P = 0.047).  
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DISCUSSION 
In this meta-analysis, we found that increased in utero exposure to 25(OH) D was inversely 
associated with risk of offspring’s wheeze and asthma in childhood, which is in adherence with 
the findings from two recent randomized clinical trials of vitamin D supplementation during 
pregnancy. The evidence was strengthened when 25 (OH) D levels were measured in cord blood. 
The observed associations were not appreciably modified by sex, outcome diagnosis methods, 
and season variation consideration in primary studies. 
 
Strengths and limitations 
One unique strength of this meta-analysis is that we obtained de novo data from a few primary 
studies,24-26 which provides more accurate and/or additional information specifically for this 
meta-analysis. Another main strength of this study is that in utero exposure to vitamin D is 
measured by objective biomarkers (i.e., cord blood or maternal venous blood) that account for 
vitamin D from diet and sun exposure. However, we realize that serum 25 (OH) D may not be 
the best biomarker, alternative vitamin D biomarkers (e.g., tissues and intracellular fluid) are 
definitely needed in future studies depending on the scale of the study and the budget and ethical 
considerations. 
 
Despite the above merits, the results should be interpreted with caution because of some 
limitations. First, moderate heterogeneity existed in some pooled analyses. The variations of 
several factors may generate the heterogeneity. For example, different study population, study 
location, sample size, duration of follow-up, source of blood samples for measuring vitamin D 
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status, outcome diagnosis, season variation consideration, and adjustment for different covariates 
in primary studies. In the analyses, a random-effects model was used in concordance with the 
heterogeneity. In addition, stratified analyses were conducted to explore any potential effect 
modifier. Second, asthma and respiratory tract infections in some primary studies and wheeze in 
all the studies were reported by parents except the COPSAC study where wheeze was diagnosed 
at acute visits to the research clinic and by a daily diary of respiratory symptoms. Although the 
signs of these health conditions may be clearly visible, the likelihood of misclassification could 
not be completely ruled out, e. g., parents might report wheeze as respiratory tract infection. 
Nevertheless, the potential misclassification should not substantially affect our results since the 
great majority of the parental reports were based on clinician’s diagnosis. Third, maternal 
25(OH) D levels in some studies were measured in venous blood during pregnancy at different 
time points. This inconsistency of the measurement time window might introduce errors in the 
exposure assessment, but this would presumably lead to a bias towards the null. However, most 
of the studies (12 out of 16) measured 25 (OD) D in the later stage of pregnancy (i.e., 2 studies at 
34-week gestation) or at birth (10 studies). Thus, the different measurement timing in a few 
studies should not substantially bias our findings. Fourth, most of the primary studies measured 
25 (OH) D levels only once, which might not adequately reflect the long-term exposure and may 
attenuate any possible associations of interest because of random variation. Our findings are 
more likely to suggest a beneficial effect of higher levels of vitamin D in late pregnancy.  Further 
longitudinal studies with repeat measurements in 25 (OH) D levels at different stages of 
pregnancy are warranted. Fifth, the baseline vitamin D levels varied across studies, but we were 
not able to adjust for this variation in the meta-analysis due to lack of original data. Sixth, we 
were not able to pool the data comparing individuals with vitamin D levels ≥75 nmol/L vs. 
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everyone else due to data insufficiency.  Finally, although the pooled analyses were based on 
fully adjusted models in the individual studies, our results might be biased by the inherent 
limitations in the primary studies such as residual confounding or confounding from unknown or 
unmeasured factors. 
 
Comparison to previous studies  
In light of the considerable complexity of the pathogenesis of these respiratory outcomes, it is 
not surprising to see the inconsistency in the available data on vitamin D status and the 
offspring’s asthma, wheeze and respiratory tract infections. One meta-analysis nested in a 
systematic review based only on 3 birth cohort studies suggested a possible association between 
low serum vitamin D levels and risk of asthma in children.21 Another review, which summarized 
data from 9 cross-sectional, 2 case-control, and 12 cohort studies in both children and adults, 
suggested that higher serum levels of 25 (OH) D were related to lower risk of asthma 
exacerbations. However, the study did not provide information on the association of in utero 
exposure to 25 (OH) D with the development of asthma in childhood.22 Notably, neither of these 
two reviews considered wheeze and respiratory tract infections as outcomes. In addition, one 
recent meta-analysis combined data from 4 cohort studies found that maternal dietary intake of 
vitamin D was associated with lower odds of offspring’s wheeze during childhood.45 However, 
dietary intake only accounts for 10% of circulating 25 (OH) D. Findings from the present meta-
analysis are generally consistent with that of the previous reviews and provide important 
additional information on in utero exposure to 25 (OH) D and risk of the offspring’s wheeze and 
respiratory tract infections in childhood. Furthermore, the findings are in line with two recently 
published randomized clinical trials of vitamin D supplementation during pregnancy showing a 
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non-significant more than 20 % reduced risk of persistent wheeze/asthma at age 0-3 years.19,20  
Of note, a recent randomized clinical trial found that the maternal or cord blood vitamin D levels 
should be at least 75 nmol/L in order to result in reversal or protection of the autoimmune effects. 
20, but the optimal level during pregnancy for lung and immune maturation is still unknown. In 
our meta-analysis, the distribution of 25 (OH) D levels varied across the primary studies, but 
overall approximately 28% participants had 25 (OH) D levels ≥ 75 nmol/L (E Table 6 at the 
Online Repository). Thus, the pooled results are biologically in concordance with findings from 
the randomized clinical trials. 
   
Possible explanations 
Vitamin D is an immune-regulator, involved in both cellular immunity and humeral immunity.46 
There are several explanations for the potential beneficial effect of vitamin D on the 
development of asthma and wheeze, including: 1) 25 (OH) D can modify T-cell differentiation 
and dendritic cell activation,17 which plays an important role in the inflammatory response; 2) 25 
(OH) D can induce a shift in the profile of cytokine secretion during an immune response to an 
anti-inflammatory phenotype, with regulatory T lymphocytes predominating in the cell 
population;47 and 3) In macrophages, vitamin D can promote antimicrobial responses through the 
induction of antibacterial proteins,18 and stimulation of autophagy and autophagosome activity.   
 
One study demonstrated a very high correlation between maternal and umbilical cord blood 
vitamin D levels (Spearman’s correlation = 0.91),48 which supports a common belief that 25 
(OH) D measured in maternal venous blood should be parallel to the measures in cord blood. 
However, we found that the association was more pronounced in the studies that 25 (OH) D was 
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measured in cord blood. Notably, the heterogeneity of the time window for measuring 25 (OH) D 
levels in maternal venous blood during pregnancy may attenuate any possible associations.  
 
Studies suggest that early lung development differs between boys and girls,49,50 which may 
explain the higher prevalence of asthma in boys than that of girls before puberty.51 Although the 
present meta-analysis did not observe sex difference, a potential effect modification of sex 
cannot be completely ruled out because the available data were derived from limited number of 
studies.11,24-26  
 
Because of seasonal variations in ultraviolet radiation exposure, seasonal variation in vitamin D 
status is recognized.52 One study found that vitamin D deficiency was marginally associated with 
an increased risk of lower respiratory tract infections in children born in fall, but not in children 
born in other three seasons.32 Some, but not all primary studies considered vitamin D seasonal 
variation in the analysis. This inconsistency may affect the pooled results and/or contribute to the 
heterogeneity. Nevertheless, seasonal variation consideration did not materially modify the 
associations of interest in this meta-analysis.  
 
CONCLUSION 
In conclusion, this meta-analysis of birth cohort studies accumulates evidence supporting that 
increased in utero exposure to 25(OH) D is inversely associated with the risk of asthma and 
wheeze during childhood. These findings are in keeping with the results of two recently 
published randomized clinical trials of vitamin D supplementation during pregnancy showing a 
more than 20% reduced risk of persistent wheeze/asthma at age 3 years.   
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FIGURE LEGENDS 
Fig 1. Flowchart of study selection 
Fig 2. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of asthma. The summary 
estimates (diamond data markers) were obtained by using a random-effects model. The dots 
indicate the adjusted ORs comparing the highest to lowest category of, or per 10 nmol/L 
increment in 25(OH) D levels. The size of the shaded square is proportional to the weight of each 
study. CI: confidence interval; OR: odds ratio. 
 
Fig 3. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of wheeze. The summary 
estimates (diamond data markers) were obtained by using a random-effects model. The dots 
indicate the adjusted ORs comparing the highest to lowest category of, or per 10 nmol/L 
increment in 25(OH) D levels. The size of the shaded square is proportional to the weight of each 
study. CI: confidence interval; OR: odds ratio. 
 
Fig 4. Multivariable-adjusted ORs and 95%CIs (horizontal lines) of respiratory tract infections. 
The summary estimates (diamond data markers) were obtained by using a random-effects model. 
The dots indicate the adjusted ORs comparing the highest to lowest category of, or per 10 
nmol/L increment in 25(OH) D levels. The size of the shaded square is proportional to the 
weight of each study. CI: confidence interval; OR: odds ratio; RTI: respiratory tract infection.  
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TABLE 1. Stratified analyses of the associations between in utero exposure to 25 (OH) D and risk of childhood asthma, wheeze and respiratory tract 
infections 
Outcome 25(OH) D Potential modifiers No. of cohorts No. of  
participants / events 
Heterogeneity  
test 
OR  
(95%CI) 
P  
for interaction 
Asthma Highest vs. lowest Overall 8 8 438/1 446 I2 =  10.4%, P = 0.349 0.84 (0.70 to1.01) -- 
 Blood source Cord blood 3 1 208/238 I2 = 33.3%, P = 0.223 0.73 (0.39 to 1.37) 0.760 
Maternal venous blood 5 7 230/1 208 I2 = 15.2%, P = 0.318 0.85 (0.70 to 1.04) 
Outcome  
assessment 
Doctor diagnosed 4 1 533/144 I2 = 13.3%, P = 0.326 0.71 (0.46 to 1.09) 0.435 
Parent-report 4 6 905/1 302 I2 = 17.8%, P = 0.302 0.88 (0.71 to 1.08) 
Season  
Considered* 
Yes 4 5 870/1 080 I2 = 21.1%, P = 0.284 0.87 (0.67 to 1.11) 0.684 
 No 4 2 567/366 I2 = 22.1%, P = 0.278 0.78 (0.56 to 1.10) 
↑ Per 10 nmol/L Overall 8 8 397/1 468 I2 = 0.0%, P = 0.520 0.99 (0.97 to 1.02) -- 
 Blood source Cord blood 4 1 455/260 I2 = 0.0%, P = 0.736 1.04 (0.98 to 1.10) 0.137 
Maternal venous blood 4 6 942/1208 I2 = 0.0%, P = 0.582 0.98 (0.96 to 1.01) 
Outcome 
 assessment 
Doctor diagnosed 3 1 253/147 I2 = 15.8%, P = 0.305 1.01 (0.93 to 1.09) 0.810 
Parent-report 5 7 144/1321 I2 = 0.0%, P = 0.439 0.99 (0.97 to 1.01) 
Season  
Considered* 
Yes 6 6 304/1 128 I2 = 11.1%, P = 0.345 1.00 (0.97 to 1.03) 0.532 
No 2 2 093/340 I2 = 0.0%, P = 0.757 0.97 (0.91 to 1.04) 
Wheeze† Highest vs. lowest Overall 8 8 694/2 150 I
2 = 62.1%, P = 0.010 0.77 (0.58 to 1.03) -- 
  Blood source Cord blood 3 1 240/612 I2 = 0.0%, P = 0.757 0.43 (0.29 to 0.62) 0.007 
 Maternal venous blood 5 7 454/1 538 I2 = 0.0%, P = 0.825 1.00 (0.83 to 1.20) 
 Season  
Considered* 
Yes 3 4 263/920 I2 = 83.2%, P = 0.003 0.60 (0.29 to 1.23) 0.427 
 No 5 4 431/1 230 I2 = 28.8%, P = 0.230 0.89 (0.67 to 1.18) 
 ↑ Per 10 nmol/L Overall  9 8 784/2 277 I2 = 5.3%, P = 0.391 0.98(0.96 to 1.004) -- 
  Blood source Cord blood 5 1 618/665 I2 = 0.0%, P = 0.438 0.95 (0.91 to 0.99) 0.074 
 Maternal venous blood 4 7 166/1 538 I2 = 0.0%, P = 0.962 1.00 (0.97 to 1.02) 
 Season  
Considered* 
Yes 5 4 641/973 I2 = 28.0%, P = 0.235 0.97 (0.94 to 1.01) 0.512 
 No 4 4 143/1 230 I2 = 0.0%, P = 0.485 1.00 (0.96 to 1.03) 
RTIs Highest vs. lowest Overall  9 7 129/2 365 I2 = 66.1%, P = 0.003 0.85 (0.66 to 1.09) -- 
  Blood source Cord blood 6 2 753/1 250 I2 = 59.8%, P = 0.029 0.74(0.53 to 1.02) 0.227 
 Maternal venous blood 3 4 426/1 115 I2 = 81.8%, P = 0.004 1.16 (0.58 to 2.30) 
 Outcome  
assessment 
Doctor diagnosed 6 5 280/1 644 I2 = 66.4%, P = 0.011 0.81 (0.61 to 1.07) 0.653 
 Parent-report 3 1 899/721 I2 = 77.0%, P = 0.013 0.95 (0.45 to 2.03) 
 Season  
Considered* 
Yes 5 3 246/1 232 I2 = 73.4%, P = 0.005 0.72 (0.41 to 1.27) 0.471 
 No 4 3 933/1 133 I2 = 58.5%, P = 0.065 0.91 (0.70 to 1.17) 
 ↑ Per 10 nmol/L Overall  9 8,153/2,500 I2 = 0.0%, P = 0.495 0.97 (0.94 to 1.01) -- 
  Blood source Cord blood 5 2 547/1 188 I2 = 0.0%, P = 0.892 0.95 (0.87 to 1.03) 0.515 
 Maternal venous blood 4 5 606/1 312 I2 = 48.0%, P = 0.123 0.98 (0.92 to 1.04) 
 Outcome  Doctor diagnosed 4 3 199/1 200 I2 = 0.0%, P = 0.878 0.94 (0.89 to 0.99) 0.120 
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 assessment Parent-report 5 4 954/1 300 I2 = 0.0%, P = 0.466 1.01 (0.95 to 1.06) 
 Season  
Considered* 
Yes 6 4 426/1 429 I2 = 0.0%, P = 0.541 0.99 (0.94 to 1.04) 0.811 
 No 3 3 727/1 071 I2 = 20.3%, P = 0.285 0.96 (0.89 to 1.04) 
25(OH) D, 25-Hydroxyvitamin D; CI, confidence interval; RTI, lower respiratory tract infection; OR, odds ratio.  
*Season of measurement of the exposure was adjusted in the model or season-standardized exposure was used. 
†Wheeze, as a symptom, was parental report in all the included studies except the COPSAC study where wheeze was diagnosed at acute visits to the research clinic and by a daily 
diary of respiratory symptoms. 
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111 Excluded after abstract review from PubMed 
       60 Not associated with asthma or wheeze or respiratory 
infections 
       39 Maternal Vitamin D not available 
     2 Maternal Vitamin D not tested from blood sample 
   10 case control studies 
249 Excluded after abstract review from EMBASE 
       170 Not associated with asthma or wheeze or 
respiratory infections 
         40 Maternal Vitamin D not available 
           6 Maternal Vitamin D not tested from blood sample 
         33 Case-control studies 
 
130 and 356 related studies identified from PubMed and EMBASE, respectively 
 
    8 Excluded from PubMed 
       5 Reviews  
       3 Case reports 
102 Excluded from EMBASE 
       28 Reviews 
       74 Case reports 
 
122 studies retrieved for abstract review from PubMed and 254 from EMBASE  
11 studies identified for full-text review from PubMed and 5 from EMBASE 
 3 Overlapped studies from two databases were excluded 
13 studies identified after full review in sum 
4 Added from the reference list 
(Other new associated articles can’t be located through the 
Google Scholar search) 
   
16 studies included in the main meta-analysis; one was only included in the sensitivity analysis 
due to low quality 
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Asthma (Highest vs. Lowest) 
 Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Magnus et al, 201310 
Wills et al, 201326 
Chawes et al, 201424 
Zosky et al, 201411 
Chiu et al, 201538 
Heterogeneity (I2 = 10.4%, P = 0.349) 
Asthma (↑ Per 10 nmol/L) 
 Camargo et al, 201137 
Rothers et al, 201142 
Morales et al, 201241 
Pike et al, 201225 
Magnus et al, 201310 
Wills et al, 201326 
Baïz et al, 201436 
Chawes et al, 201424 
Heterogeneity (I2 = 0.0%, P = 0.520) 
Study 
1.06 (0.60 to 1.87) 
0.89 (0.60 to 1.33) 
1.04 (0.60 to 1.80) 
0.67 (0.48 to 0.94) 
1.00 (0.75 to 1.33) 
0.61 (0.11 to 3.48) 
0.55 (0.24 to 1.26) 
0.44 (0.19 to 1.02) 
0.84 (0.70 to 1.01) 
1.03 (0.97 to 1.10) 
1.13 (0.95 to 1.35) 
0.95 (0.80 to 1.13) 
0.98 (0.91 to 1.05) 
0.95 (0.90 to 1.01) 
1.00 (0.96 to 1.04) 
1.06 (0.82 to 1.35) 
1.00 (0.84 to 1.19) 
0.99 (0.97 to 1.02) 
OR (95%CI) 
9.53 
17.38 
10.04 
22.86 
30.01 
1.09 
4.59 
4.50 
100.00 
16.10 
2.12 
2.17 
11.45 
19.17 
45.84 
1.04 
2.11 
100.00 
Weight, % 
  
0.25 0.5 1.0 2.0 4.0 
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Wheeze (Highest vs. Lowest) 
 Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Wills et al, 201326 
Chawes et al, 201424 
de Jongh et al, 201431 
Zosky et al, 201411 
Stelmach et al, 201544 
Heterogeneity (I2 = 62.1%, P = 0.010) 
Wheeze (↑ Per 10 nmol/L) 
 
Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Wills et al, 201326 
Baïz et al, 201436 
Chawes et al, 201424 
de Jongh et al, 201431 
Jones et al, 201539 
Stelmach et al, 201544 
Heterogeneity (I2 = 5.3%, P = 0.391) 
Study 
0.47 (0.30 to 0.72) 
0.94 (0.62 to 1.43) 
0.94 (0.66 to 1.33) 
1.06 (0.78 to 1.44) 
0.32 (0.11 to 0.95) 
1.25 (0.72 to 2.15) 
0.76 (0.37 to 1.59) 
0.36 (0.14 to 0.89) 
0.77 (0.58 to 1.03) 
0.95 (0.91 to 0.99) 
0.97 (0.88 to 1.07) 
1.00 (0.96 to 1.05) 
1.00 (0.97 to 1.02) 
1.12 (0.82 to 1.52) 
0.90 (0.78 to 1.04) 
1.00 (0.90 to 1.11) 
0.95 (0.77 to 1.18) 
0.00 (0.00 to 8.55) 
0.98 (0.96 to 1.00) 
OR (95%CI) 
 
14.98 
15.41 
12.64 
9.26 
7.05 
100.00 
22.25 
4.79 
19.82 
45.35 
0.48 
2.15 
4.17 
0.98 
0.00 
100.00 
Weight, % 
16.95 
18.12 
5.59 
0.25 0.5 1.0 2.0 4.0 
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RTIs (Highest vs. Lowest) 
 Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Mohamed et al, 201340 
Shin et al, 201343 
Chawes et al, 201424 
de Jongh et al, 201431 
Luczynska et al, 201432 
Stelmach et al, 201544 
Heterogeneity (I2 = 66.1%, P = 0.003) 
RTIs (↑ Per 10 nmol/L) 
 
Camargo et al, 201137 
Morales et al, 201241 
Pike et al, 201225 
Magnus et al, 201310 
Shin et al, 201343 
Chawes et al, 201433 
de Jongh et al, 201431 
Luczynska et al, 201432 
Stelmach et al, 201544 
Heterogeneity (I2 = 0.0%, P = 0.495) 
Study 
0.49 (0.27 to 0.88) 
0.67 (0.50 to 0.90) 
1.68 (0.94 to 2.99) 
0.93 (0.91 to 0.95) 
0.28 (0.12 to 0.66) 
0.78 (0.34 to 1.81) 
1.58 (0.80 to 3.14) 
0.89 (0.54 to 1.47) 
1.05 (0.51 to 2.17) 
0.85 (0.66 to 1.09) 
0.90 (0.74 to 1.09) 
0.93 (0.87 to 0.99) 
1.03 (0.96 to 1.11) 
0.93 (0.81 to 1.07) 
0.90 (0.71 to 1.13) 
0.98 (0.86 to 1.11) 
1.03 (0.92 to 1.15) 
0.95 (0.78 to 1.16) 
5.34 (0.01 to 2360.83) 
0.97 (0.94 to 1.01) 
OR (95%CI) 
9.96 
17.08 
10.21 
22.35 
6.20 
6.31 
8.36 
11.79 
7.75 
100.00 
3.80 
33.09 
29.20 
7.69 
2.59 
9.00 
10.94 
3.70 
0.00 
100.00 
Weight, % 
0.25 0.5 1.0 2.0 4.0 
